Chemical Properties:
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.Manufacturer Supply with High Purity and Stable Quality Chemical Name: Lopinavir CAS: 192725-17-0 A Highly Potent, Selective Peptidomimetic HIV-1 Protease Inhibitor COVID-19 Related Research Product API High Quality, Commercial Production| Item | Specifications |
| Appearance | White to Off-White Powder |
| Solubility | Freely Soluble in Methanol and in Ethanol, Soluble in 2-Propanol |
| Identification IR | The infrared absorption spectrum of the test sample is concordant with the spectrum of reference standard |
| Identification HPLC | The retention time of the test sample corresponds to that of the reference standard |
| Water Content (by K.F) | ≤4.0% |
| Specific Optical Rotation | -22.0° to -26.0° |
| Residue on Ignition | ≤0.20% |
| Heavy Metals | ≤20ppm |
| Melting Point | 124.0 to 127.0℃ |
| Sulphated Ash | ≤0.20% |
| Residual Solvent (Ethanol) | ≤0.50% |
| Related Substances | (HPLC, Area%) |
| Impurity 1 | |
| Impurity B (RRT=0.07) | ≤0.20% |
| Impurity I (RRT=1.10) | ≤0.20% |
| Any Other Impurity | ≤0.10% |
| Impurity 2 | Any Other Individual Impurity ≤0.10% |
| Total Impurities from Procedure 1 and 2 | ≤0.70% |
| Total Impurities | ≤1.0% |
| Assay (by HPLC) | 98.0%~102.0% |
| Test Standard | Enterprise Standard |
| Usage | Selective Peptidomimetic HIV-1 Protease Inhibitor, COVID-19 Related Research Product |
Description:
Specifications:
Package & Storage:
| Chemical Name | Lopinavir |
| Synonyms | LPV; ABT-378; Kaletra |
| CAS Number | 192725-17-0 |
| CAT Number | RF-API73 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C37H48N4O5 |
| Molecular Weight | 628.81 |
| Long-Term Storage | Store Long-term at 2-8℃ |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM. Lopinavir is an antiretroviral of the protease inhibitor class. Inhibition of HIV-1 protease prevents cleavage of the viral polyprotein precursor and results in the release of immature, noninfectious virions. A component of combination therapy to treat HIV/AIDS. Lopinavir, the sixth HIV protease inhibitor in the “navir” class, was launched in coformulation with ritonavir, another HIV protease inhibitor already marketed (Abbott, 1996); this original formulation was introduced as Kaletra for use in combination with either nucleoside or non-nucleoside reverse transcriptase inhibitors for the treatment of AIDS in adults and children. Lopinavir is a peptidomimetic compound with a structural core identical to that of ritonavir, on which terminal groups, particularly a modified valine, were introduced by peptide coupling procedures. Lopinavir is a potent competitive inhibitor of HIV-I protease exhibiting high potential against ritonavir-resistant mutations. In several animal species, pharmacokinetic studies with the lopinavirlritonavir association showed that the modest properties of lopinavir were significantly improved in presence of ritonavir, in terms of Cmax and duration of action.
